Clinical Trials
> Colon/Rectal
Cancer

REMUCIRUMAB

A randomized Phase II study of Irinotecan and Cetuximab with or without the anti-angiogenic antibody, Ramucirumab, in advanced K-ras wild-type colorectal cancer following progression on Bevacizumab-containing chemotherapy.